Effect of Insulin-like Growth Factor-1 (IGF-1) Plus Alendronate on Bone Density During Puberty in IGF-1-deficient MIDI Mice
Overview
Affiliations
Insulin-like growth factor-1 (IGF-1) increases both bone formation and bone resorption processes. To test the hypothesis that treatment with an antiresorber along with IGF-1, during the pubertal growth phase, would be more effective than IGF-1 alone to increase peak bone mass, we used an IGF-1 MIDI mouse model, which exhibits a >60% reduction in circulating IGF-1 levels. We first determined an optimal IGF-1 delivery by evaluating IGF-1 administration (2 mg/kg body weight/day) by either a single daily injection, three daily injections, or by continuous delivery via a minipump during puberty. Of the three regimens, the three daily IGF-1 injections and IGF-1 through a minipump produced a significant increase in total body bone mineral density (BMD) (6.0% and 4.4%, respectively) and in femoral BMD (4.3% and 6.2%, respectively) compared with the control group. Single subcutaneous (s.c.) administration did not increase BMD. We chose IGF-1 administration three times daily for testing the combined effects of IGF-1 and alendronate (100 microg/kg per day). The treatment of IGF-1 + alendronate for a period of 2 weeks increased total body BMD at 1 week and 3 weeks after treatment (21.1% and 20.5%, respectively) and femoral BMD by 29% at 3 weeks after treatment. These increases were significantly greater than those produced by IGF-1 alone. IGF-1, but not alendronate, increased bone length. IGF-1 and/or alendronate increased both periosteal and endosteal circumference. Combined treatment caused a greater increase in the total body bone mineral content (BMC) and periosteal circumference compared with individual treatment with IGF-1 or alendronate. Our data demonstrate that: (1) inhibition of bone turnover during puberty increases net bone density; and (2) combined treatment with IGF-1 and alendronate is more effective than IGF-1 or alendronate alone in increasing peak bone mass in an IGF-1-deficient MIDI mouse model.
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis.
Estell E, Rosen C Nat Rev Endocrinol. 2020; 17(1):31-46.
PMID: 33149262 DOI: 10.1038/s41574-020-00426-5.
Insulin-like growth factors: actions on the skeleton.
Yakar S, Werner H, Rosen C J Mol Endocrinol. 2018; 61(1):T115-T137.
PMID: 29626053 PMC: 5966339. DOI: 10.1530/JME-17-0298.
The somatotropic axis and aging: Benefits of endocrine defects.
Bartke A, List E, Kopchick J Growth Horm IGF Res. 2016; 27:41-45.
PMID: 26925766 PMC: 4792645. DOI: 10.1016/j.ghir.2016.02.002.
Yakar S, Isaksson O Growth Horm IGF Res. 2015; 28:26-42.
PMID: 26432542 PMC: 4809789. DOI: 10.1016/j.ghir.2015.09.004.
Growth hormone regulates the balance between bone formation and bone marrow adiposity.
Menagh P, Turner R, Jump D, Wong C, Lowry M, Yakar S J Bone Miner Res. 2009; 25(4):757-68.
PMID: 19821771 PMC: 3153330. DOI: 10.1359/jbmr.091015.